Autres langues Oncodesign Precision Medicine

Actions

ALOPM

FR001400CM63

Marché Fermé - Euronext Paris Autres places de cotation 17:28:51 30/05/2024			Varia. 5j.	Varia. 1 janv.
1,29 ^EUR	0,00 %		+3,61 %	-28,73 %

15/05	Oncodesign Precision Medicine et Navigo Proteins GmbH signent un accord de collaboration stratégique pour la recherche et le développement de nouveaux agents de radiothérapie systémique	CI
18/04	Oncodesign obtient un financement public de 5,6 millions d'euros	AO

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents	15/05
Oncodesign Precision Medicine and Navigo Proteins GmbH Sign A Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents	15/05
Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine	18/04
Wall Street en busca de un nuevo catalizador	18/04
Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101	17/04
OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments	26/03
Oncodesign Precision Medicine : OPM publishes its annual results for 2023 and provides an update on its clinical developments	26/03
Bolsa de Madrid: Los mercados van viento en popa	01/03
Oncodesign Precision Medicine : une levée de fonds se profile	25/01
Oncodesign Precision Medicine Receives ERDF Fund Totalling ?2.1 Million for its Comete Program	25/01
Eurazeo : entrée au capital d'Oncodesign Services	23/01
Oncodesign Precision Medicine Société anonyme announced that it has received ?22 million in funding from Eurazeo SE and other investors	23/01
Oncodesign Precision Medicine Société anonyme acquired Zobio B.v.	23/01
Bolsa de Madrid: ¿Por fin malas noticias?	06/10/23
Oncodesign Precision Medicine Obtains EUR6 Million Loan from Regional Banks	06/10/23
Oncodesign Precision Medicine Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers	02/10/23
Bolsa de Madrid: La cuadratura del círculo	20/09/23
Oncodesign Precision Medicine Société Anonyme Approves the Nomination of Florence Dupré to the Board of Directors	30/05/23
Oncodesign Precision Medicine : OPM announces its 2022 results	13/04/23
Oncodesign : lancement d'un essai clinique dans les MICI	10/02/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Oncodesign Precision Medicine

Actions

ALOPM

FR001400CM63

Autres langues

Filtres